Diabetic Foot Ulcers and Comprehensive Wound Care

Executive Summary

A diabetic (diabetes-related) foot ulcer (DFU) is a full-thickness break in the skin below the ankle in a person with diabetes. At the origin of the clinical picture there is usually a convergence of three factors: peripheral neuropathy, peripheral arterial disease (PAD), and biomechanical or repetitive trauma. Hyperglycaemia, immune dysfunction, and impaired healing secondary to microvascular disease compound this substrate further [1,2,3].

DFUs are both common and dangerous. The lifetime risk of a foot ulcer in people with diabetes is roughly 19–34% [1,2,4]. Global point prevalence among people with diabetes is approximately 6.3% [5]; some 18.6 million people worldwide are affected each year [3]. Most non-traumatic lower-extremity amputations in diabetes (roughly 80%) are preceded by an ulcer [3,4]. Even after healing, these ulcers should be regarded as being in remission rather than cured: recurrence reaches approximately 40% within 1 year, ~60% at 3 years, and 65% at 5 years [2,3]. Five-year mortality after a DFU is by no means trivial — estimates range from ~30% in some reviews to ~40–50% in others, largely cardiovascular in origin — and after major amputation it exceeds 70%, a course worse than that of many common cancers [2,3,4].

The principal determinants of healing and amputation risk are well established: the adequacy of perfusion (ischaemia is the dominant cause of non-healing and amputation); the presence and severity of infection, particularly osteomyelitis and deep/necrotising infection; ulcer depth and size; effective pressure offloading in plantar neuropathic ulcers; and access to multidisciplinary care [1,5,6,7].

The treatment principles with the most robust support — in short, the "standard care bundle" — can be summarised as follows: (1) assess perfusion, restore it, and revascularise significant ischaemia; (2) diagnose and treat infection appropriately, managing osteomyelitis by its own distinct rules; (3) debride non-viable tissue (sharp/surgical debridement is first line for most wounds, with caution in ischaemia); (4) offload plantar neuropathic ulcers, ideally with a non-removable knee-high device — a total contact cast or a walker rendered non-removable; (5) maintain moisture balance with simple dressings selected according to exudate, comfort, and cost; (6) optimise glycaemia, nutrition, and comorbidities; (7) educate the patient; (8) reassess regularly within a multidisciplinary team [1,5,6,7,8].

Standard, adjunctive, and experimental. Offloading, debridement, infection control, and revascularisation are the evidence-based cornerstones of treatment. Alongside these, a limited set of adjunctive therapies carries conditional guideline support only after best standard care has failed to advance the wound and where resources permit: sucrose octasulfate dressing (non-infected neuroischaemic ulcers), autologous leucocyte/platelet/fibrin patch, placenta-derived membrane products, negative pressure wound therapy (NPWT — for postoperative foot wounds), hyperbaric oxygen (HBOT — in neuroischaemic ulcers), and topical oxygen [7,8]. Most other advanced therapies — stem cells, exosomes, growth factors, cold plasma, phage, bioprinting, and the bulk of cellular products — remain investigational or inadequately supported for routine use. Certain dressings and additives are explicitly not recommended for healing purposes alone (e.g. collagen/alginate for healing, topical phenytoin, herbal-impregnated dressings) [7].

Definition and Clinical Importance

Core definitions (consistent with IWGDF 2023 terminology) [1]:

• Diabetic (diabetes-related) foot ulcer (DFU): a full-thickness skin defect (extending through the dermis) below the malleoli in a person with diabetes; partial-thickness lesions and pre-ulcerative lesions are its precursors.
• Diabetic foot infection (DFI): the host inflammatory response and tissue destruction resulting from invasion and multiplication of microorganisms in the soft tissue of the foot. The diagnosis is made clinically, not by culture alone, on the basis of ≥2 signs of inflammation (erythema, warmth, tenderness/pain, induration/swelling, purulent discharge) [5].
• Neuropathic ulcer: an ulcer in a foot with sensory loss but adequate perfusion; typically over pressure points (plantar metatarsal heads, toes, heel), usually painless and surrounded by callus. The primary cause is loss of protective sensation and deformity.
• Ischaemic ulcer: an ulcer in which significant PAD is the dominant factor; typically at the margins and tips of the toes/heel, painful, with signs of poor perfusion. Healing potential is poor without revascularisation.
• Neuroischaemic ulcer: the combination of neuropathy and PAD; the most common and highest-risk phenotype in modern cohorts.
• Gangrene: tissue death due to critical ischaemia. Dry gangrene (mummified, ischaemic, usually demarcated) is distinguished from wet gangrene (infected, liquefactive — a surgical emergency).
• Diabetic foot osteomyelitis (DFO): infection of the bone underlying an ulcer, most often by contiguous spread; one of the leading causes of amputation and prolonged treatment.

Burden. DFUs impose a heavy burden: clinical (amputation, mortality), economic (they are among the most expensive complications of diabetes — hospital admissions and inpatient days exceed those of several cancers), functional (loss of mobility and employment), and quality of life (pain, depression, social isolation) [2,3,4]. The link between DFU and amputation is direct and central: ulcers precede roughly 80% of lower-extremity amputations in diabetes, making DFU the leading cause of non-traumatic lower-extremity amputation, with infection and ischaemia as the proximate factors [3,4].

Epidemiology

All the figures below are labelled with source and year; unless otherwise stated they are taken from peer-reviewed reviews and 2023–2024 WHO/IWGDF consensus data. Regional and methodological heterogeneity is marked, so read the ranges as approximate values. Where the two source reviews diverge, both estimates are shown.

Regional variation and disparities. After a preceding period of decline, amputation incidence has risen again in recent years in some regions by as much as ~50%; this increase is particularly marked among younger people and among racial/ethnic minorities. Black, Hispanic, and Native American patients, and people of low socioeconomic status, carry a higher risk of ulcers progressing to amputation [2,3]. Behind this lie inequitable access to multidisciplinary foot care, late presentation, PAD severity, and socioeconomic barriers [2]. In low-resource settings, late presentation and limited team-based/vascular surgical care worsen outcomes and raise amputation rates [1].

Pathophysiology

DFU formation is multifactorial. The classic causal pathway runs: neuropathy + minor trauma + (usually) ischaemia → ulceration → impaired healing → infection [2,3,6].

Peripheral neuropathy is the central predisposing factor and causes damage along three axes:

• Sensory: loss of protective sensation disables the warning system; repetitive trauma and foreign bodies go unnoticed.
• Motor: wasting/atrophy of the intrinsic muscles leads to claw or hammer toes, altered loading, and prominence of the metatarsal heads; the result is focal high plantar pressure.
• Autonomic: loss of sweating produces dry, fissured skin; there is also abnormal arteriovenous shunting and impaired regulation of the microcirculation.

Vascular disease. At the macrovascular level, PAD reduces bulk perfusion and the delivery of oxygen and nutrients; in diabetes, atherosclerosis appears earlier and more distally, producing characteristic tibial and below-knee disease together with medial arterial calcification. The accompanying microvascular dysfunction (capillary basement membrane thickening, endothelial dysfunction, impaired vasodilatation and hyperaemic response) further restricts tissue oxygenation and the delivery of immune cells [2,6].

Impaired healing biology. Hyperglycaemia and its consequences sabotage healing on many fronts: immune dysfunction (impaired neutrophil chemotaxis and phagocytosis); chronic low-grade inflammation (a persistent pro-inflammatory M1 macrophage state, with high levels of proteases/MMPs that degrade growth factors and matrix); oxidative stress; advanced glycation end-products (AGEs) that stiffen collagen and impair fibroblast function; impaired angiogenesis (dysregulated VEGF signalling); abnormal collagen synthesis and turnover; and rapid biofilm formation, in which wound bacteria acquire resistance to host defences and antimicrobials. Together these convert the course of an acute wound into a stalled, chronic one [2,6,7].

The mechanical cascade. Deformity and limited joint mobility lead to repetitive peak pressure, which produces callus — the callus itself acting almost as a foreign body and raising pressure still further — followed by subkeratotic haemorrhage and then ulceration. Once ischaemia (poor healing) and infection (tissue destruction) enter the picture, the wound enlarges and deepens towards tendon, joint, and bone.

Risk Factors

Established risk factors for ulceration, poor healing, infection, amputation, and/or recurrence [1,2,10]:

• Long duration of diabetes
• Poor glycaemic control (early intensive control may confer a lasting "metabolic memory" protection) [28]
• Previous ulcer or amputation (one of the strongest predictors of recurrence)
• Peripheral neuropathy / loss of protective sensation
• Peripheral arterial disease (the dominant driver of non-healing and amputation)
• Foot deformity (claw toes, Charcot, hallux valgus, previous surgery)
• Callus (plantar) and high plantar pressure
• Limited joint mobility
• Chronic kidney disease, particularly dialysis (markedly increased risk of ulceration and amputation)
• Smoking
• Visual impairment / retinopathy (makes self-examination difficult)
• Poor or ill-fitting footwear
• Reduced mobility / gait instability
• Malnutrition
• Social and economic barriers (access, cost, transport)
• Inadequate self-care / low health literacy
• Depression or cognitive impairment
• History of infection

Initial Clinical Assessment

A structured assessment covers four levels at once: the person, the limb, the foot, and the wound.

History framework

• Type/duration of diabetes, glycaemic control (HbA1c), medications
• Ulcer history: onset, duration, precipitating trauma/footwear, previous ulcers/amputations, previous treatments
• PAD symptoms (claudication, rest pain — often absent or atypical in neuropathy) and neuropathy (numbness, paraesthesia, burning)
• Systemic symptoms (fever, malaise, glycaemic decompensation — may be blunted)
• Comorbidities (CKD/dialysis, cardiovascular disease, immunosuppression), smoking, nutrition, vision, mobility, social support, mental health
• Vaccination/tetanus status where relevant

Wound examination — document systematically

• Site (plantar pressure point, margin/tip, heel, or interdigital)
• Dimensions (length × width in mm) and depth; presence of undermining and tunnelling/sinus tracts
• Exudate (volume, type) and odour
• Wound bed (granulation, slough/fibrinous tissue, necrosis/eschar), callus at the edges
• Periwound skin: erythema, oedema, warmth, maceration, fluctuance, crepitus
• Exposed structures: tendon, joint capsule, or bone (probe-to-bone)

Documentation. Standardised serial photography (consistent lighting, scale, and angle), planimetry or acetate tracing, and serial measurement together allow objective tracking of percentage area reduction over time [1,27].

Pain assessment. Grade and characterise the pain; but remember that in neuropathic patients severe ischaemia may run a relatively painless course.

Neurological testing. Assess with the 10-g Semmes-Weinstein monofilament (loss of protective sensation), 128-Hz tuning fork vibration, pinprick, ankle reflexes, and thermal sensation; the Ipswich touch test is a simple validated bedside alternative for screening [23].

Vascular examination. Palpate the dorsalis pedis and posterior tibial pulses; assess capillary refill, skin temperature, dependent rubor, elevation pallor, hair loss, and tissue loss — then confirm the findings with objective testing (Section 9).

Musculoskeletal/biomechanical assessment. Deformities, range of motion, gait, footwear inspection, plantar pressure distribution, and callus pattern; in other words, a map of where pressure is concentrated.

Classification Systems

No single system serves every purpose. Diagnostic/severity systems (PEDIS, IWGDF/IDSA infection), prognostic/anatomical systems (Wagner, University of Texas [UT], SINBAD), and perfusion/limb-threat systems (WIfI) answer different questions. The IWGDF 2023 classification guideline recommends selecting the system according to purpose: SINBAD for communication and audit, IWGDF/IDSA for infection, WIfI for perfusion and limb-threat triage, and SINBAD or UT for individual prognosis [6].

Practical value. Use the perfusion + infection + wound framework at every assessment. WIfI is particularly useful in deciding on the urgency of revascularisation; the IWGDF/IDSA scheme guides antibiotic and hospitalisation decisions; and SINBAD/UT support prognosis and communication between centres [6].

Laboratory and Diagnostic Tests

Blood tests. Full blood count; CRP, ESR, and procalcitonin (PCT) where indicated; comprehensive metabolic panel and renal function (guiding antibiotic dosing and contrast decisions); liver function; glucose and HbA1c; electrolytes; and nutritional markers (albumin/prealbumin — imperfect, affected by inflammation). Inflammatory markers support the diagnosis when clinical findings remain uncertain [5].

Cultures

• Do not culture clinically uninfected ulcers.
• In clinically infected wounds, cleanse and debride first, and take cultures after debridement; preferably by aseptic deep tissue curettage or biopsy rather than a superficial swab (swabs overstate colonisers and surface contaminants) [5,7].
• Bone culture/biopsy is the gold standard for diagnosing osteomyelitis and identifying pathogen/susceptibility, particularly when empirical treatment has failed or in order to guide prolonged therapy [5].
• Take blood cultures in the presence of systemic signs or sepsis.
• IWGDF/IDSA 2023 recommends conventional culture over molecular techniques for routine pathogen identification [5].

Imaging

• Plain radiography is first line (deformity, gas, foreign body, bone destruction; also first line for DFO/Charcot). It may appear normal early in osteomyelitis — repeat at 2–4 weeks if suspicion persists.
• MRI is the most sensitive/specific imaging for osteomyelitis and soft tissue abscess when radiographs are inconclusive.
• CT is used for bone detail and gas when MRI is contraindicated; ultrasound for abscess and fluid collections.
• Nuclear imaging / labelled leucocyte scan / PET as an adjunct when MRI is unavailable or equivocal (for example, to distinguish Charcot from osteomyelitis).

Probe-to-bone (PTB) test. A sterile blunt probe reaching hard, gritty bone increases the likelihood of osteomyelitis; it carries a high positive predictive value in a high-prevalence (infected) setting. It has limitations: sensitivity and specificity depend on pre-test probability, so a positive PTB in a low-risk clean wound is less conclusive, and a negative PTB does not entirely exclude DFO. It performs best in combination with radiography and inflammatory markers [5].

Diagnostic criteria for DFO typically combine: a positive PTB, raised inflammatory markers, suggestive radiographic/MRI findings, and — for definitive diagnosis — positive bone histology/culture [5].

Vascular Assessment

Perfusion is the single most important determinant of healing and limb salvage; every DFU therefore requires a perfusion assessment [1,11].

The IWGDF/ESVS/SVS PAD guideline stresses that no single perfusion threshold can reliably predict healing; evaluate the tests together with the clinical context, and lower the threshold for investigation when a wound is not progressing [11].

Anatomical imaging. Duplex ultrasound (first-line non-invasive mapping), CT angiography, MR angiography, and catheter/digital subtraction angiography are used. Detail of below-knee and pedal disease is important for angiosome-directed planning.

Infection Assessment

Distinguishing colonisation from infection is essential: all chronic wounds are colonised, but infection is a clinical diagnosis based on local/systemic inflammation, not on culture positivity [5].

Local signs: purulence, erythema, warmth, tenderness/pain, induration/swelling, friable or discoloured granulation, malodour, and non-healing. Systemic signs: fever, rigors, tachycardia, hypotension, confusion, leucocytosis, and hyperglycaemia/metabolic decompensation.

Atypical presentation. In ischaemic or immunosuppressed patients (including CKD/dialysis) the signs may be blunted; deep infection may present as unexplained glycaemic instability accompanied by subtle changes. Maintain a low threshold for deep infection accordingly.

Hospital admission criteria (IWGDF/IDSA): severe infection; or moderate infection accompanied by complicating factors (e.g. significant ischaemia, inability to care for the wound at home, need for IV antibiotics/urgent surgery, poor metabolic control) [5].

Core Principles of Standard Wound Care

The following are the evidence-based cornerstones; it should be remembered that no dressing or adjunctive therapy substitutes for them [1,7,8]:

1. Pressure reduction / offloading (Section 15) — essential for plantar neuropathic ulcers.
2. Debridement of non-viable tissue and callus (Section 12).
3. Infection control — diagnose and treat appropriately; do not overtreat colonisation (Section 18).
4. Restoration of perfusion — assess and revascularise significant ischaemia (Sections 9, 20).
5. Moisture balance — a moist wound bed with protected edges; avoid maceration (Section 14).
6. Oedema management — treat contributing cardiac/venous/renal causes.
7. Glycaemic optimisation — individualised targets (Section 16).
8. Nutritional assessment/support — correct deficiencies (Section 17).
9. Smoking cessation.
10. Treatment of comorbidities (CKD, cardiovascular disease, anaemia).
11. Patient education (Sections 29–30).
12. Regular reassessment with objective wound measurement (Section 27).
13. Multidisciplinary care (Section 26).

Debridement

Debridement removes necrotic tissue, callus, slough (fibrinous tissue), senescent cells, and biofilm in order to return a chronic wound to an acute healing course. In most DFUs, sharp/surgical debridement is first line and is repeated as required [1,7].

Wound Cleansing and Antiseptics

For routine cleansing, sterile normal saline or potable (drinkable) water is sufficient in most DFUs; gentle irrigation removes loose debris, and commercial cleansers have no proven healing advantage in routine use [1].

Why can routine antiseptics delay healing?

Several agents are cytotoxic to fibroblasts and keratinocytes at in-use concentrations; prolonged, indiscriminate application to clean, granulating tissue can therefore impair healing. Reserve antiseptics for infected or heavily bioburdened wounds, prefer agents with lower cytotoxicity (dilute hypochlorous acid, PHMB), and stop once the bioburden is under control [1,3,7].

Dressing Selection

The core principle of IWGDF 2023 is clear: select dressings primarily on the basis of exudate control, comfort and cost — the evidence does not show any advanced dressing to be superior to another in terms of healing [7]. There is no single dressing that suits every DFU.

Bottom line: in most DFUs, choose a simple, cost-effective dressing matched to exudate and comfort. Reserve antimicrobial dressings for infected/critically colonised wounds, and sucrose octasulfate for the specific evidence-based niche above. According to IWGDF 2023, do not use collagen or alginate for the purpose of healing [7].

Offloading and Biomechanical Management

Offloading is the single most important intervention for healing plantar neuropathic ulcers; without it, other measures frequently fail to deliver [1,12].

The IWGDF 2023 hierarchy for a plantar neuropathic forefoot ulcer [1,12]:

1. First choice: a non-removable knee-high device — either a total contact cast (TCC) or a removable walker rendered non-removable (instant TCC). These maximise both offloading and adherence.
2. If a non-removable device is contraindicated or not tolerated: a removable knee-high walker (provide intensive education on adherence).
3. If knee-high is not feasible: a removable ankle-high device.
4. Otherwise: felted foam and appropriate footwear as an interim measure or last resort.

Adherence is the key differentiating factor here: non-removable devices heal faster largely because they cannot be removed. Contraindications cluster around infection, ischaemia, oedema, balance/falls risk and tolerance — assess each before casting [1,12].

Surgical offloading comes into play for ulcers that recur or fail to heal because of fixed deformity or pressure: Achilles tendon lengthening (reduces forefoot pressure), tendon transfers and balancing, metatarsal head resection/osteotomy, digital procedures, exostectomy and deformity correction. When conservative offloading proves inadequate, these procedures can achieve healing and prevent recurrence — at the cost of surgical risk and possible transfer lesions [1].

Glycaemic and Metabolic Management

Chronic hyperglycaemia is the best-established modifiable factor for microvascular complications; glycaemic optimisation supports healing and reduces complication risk. That said, the direct effect size on healing of an established ulcer is modest and entangled with confounders [16,28].

Individualised targets. Targets are highly personal (commonly an HbA1c of around 7–8%) and balance wound-healing needs against hypoglycaemia risk, renal failure, malnutrition/frailty and acute infection (which itself worsens control). Severe hyperglycaemia impairs neutrophil function. The ADA 2026 Standards exemplify individualisation over uniformly tight control, for instance by suggesting an A1C target of <8% within three months after elective surgery in relevant contexts [16].

"Metabolic memory". Early intensive glucose control may reduce future DFU and amputation risk even after subsequent rises in HbA1c, which supports aggressive initial management [28].

Drug classes (educational, not a prescription). Insulin and non-insulin agents each have a role; the choice is individualised according to glycaemia, renal function, cardiovascular/renal indications and hypoglycaemia risk.

Class-specific historical limb concerns. Some glucose-lowering drug classes have been scrutinised for possible amputation-signal associations in trials; overall the evidence has been mixed and context-dependent. Decisions should follow current cardiometabolic guidance and specialist opinion rather than avoidance based on a single historical signal. State this uncertainty openly to patients and colleagues.

Nutritional Assessment and Support

Screen for protein-calorie malnutrition, which is common and impairs healing; CKD/dialysis, frailty and sarcopenia are frequent contributors.

Chronic wounds increase basal metabolic rate and protein-energy demands; ensure adequate intake. A commonly cited target is approximately 1.2–1.5 g/kg/day of protein (individualised; patients with renal disease require specific protein targets) [9].

Correct documented deficiencies (e.g. vitamin D, vitamin B12, iron, vitamin C, zinc). By contrast, the evidence for routine supplementation in the absence of deficiency (including arginine, omega-3 and "wound-healing" formulations) is weak and inconsistent. Distinguish correction of deficiency from blanket supplementation.

Address obesity, sarcopenia and dialysis-related nutritional problems within a dietitian-led plan.

Antibiotic Therapy

Empirical therapy is guided by infection severity, previous antibiotics, local resistance patterns, renal function, allergies and the likely organisms [5]:

• In mild and many chronic cases the causative organisms are predominantly aerobic gram-positive cocci (Staphylococcus aureus, streptococci); narrow-spectrum oral agents are usually sufficient.
• In moderate–severe, chronic, previously treated or warm-climate/macerated cases, broaden cover to include gram-negatives and, where risk factors are present, anaerobes. Empirical MRSA cover is considered if MRSA is locally prevalent or risk factors are present; empirical anti-pseudomonal cover is considered when P. aeruginosa is a documented recent isolate or in specific high-risk contexts (IWGDF/IDSA recommend targeted rather than universal Pseudomonas cover) [5].
• Avoid unnecessary broad-spectrum therapy; de-escalate promptly on the basis of deep tissue culture and clinical response.

Route. Given adequate bioavailability, oral therapy is appropriate for most mild–moderate infections; IV is preferred for severe infection, systemic illness, inability to tolerate oral intake or specific organisms — with early IV-to-oral switch once the patient is stable.

Duration (guideline-based, individualised) [5]:

• Soft tissue infection: guided by response, typically about 1–2 weeks in mild cases and up to 2–3 weeks in moderate–severe cases.
• Osteomyelitis: approximately 6 weeks when managed medically or when infected bone is not completely resected; shorter (e.g. days up to about 1–3 weeks) when infected bone has been surgically resected to clean margins (see Section 19).

Stewardship. The principle is clear: the shortest effective duration, the narrowest effective spectrum, culture-directed de-escalation and reassessment. IWGDF/IDSA 2023 recommend not combining topical and systemic antibiotics in soft tissue DFI (conflicting evidence) [5].

Management of Osteomyelitis

Diagnosis (Section 8) combines PTB, inflammatory markers (ESR/CRP), radiography/MRI and — for definitive diagnosis — bone biopsy histology/culture [5].

Deciding between medical and surgical management:

• Primarily medical (antibiotic) management is reasonable for selected cases: forefoot DFO without extensive necrosis or abscess, adequate perfusion, no urgent surgical indication and reliable follow-up — including patients who are poor surgical candidates. In this situation, prolonged culture-directed therapy (approximately 6 weeks) is typically given [5].
• Surgical resection of infected bone is preferred where structurally appropriate and is indicated in the following circumstances: extensive/necrotic bone, an accompanying abscess or soft tissue destruction, spreading/severe infection, deformity requiring correction, or failure of medical therapy. Resecting infected bone to clean margins substantially shortens the required antibiotic duration [5].
• Bone biopsy/culture should guide prolonged regimens, particularly when empirical therapy has failed.

Follow-up. Track clinical response, serial inflammatory markers and imaging over time (serial plain films may lag behind clinical improvement). Distinguish remission from cure; surveillance for recurrence is essential, and re-ulceration at the same site should trigger reassessment for residual or recurrent DFO.

Revascularisation

When perfusion is inadequate for healing given the wound and infection burden, revascularisation becomes central to limb salvage [11].

Endovascular versus open surgery. Both are effective; the choice depends on lesion anatomy, extent, availability of a graft (autologous vein), patient risk and local experience. In contemporary practice an endovascular-first approach is often taken — preferred for frail patients and multilevel disease — while open bypass is reserved for long occlusions and risk-appropriate patients with a good autologous vein graft; the decision is individualised through a vascular multidisciplinary team [11].

Angiosome-directed revascularisation (targeting the artery supplying the wound's territory) is a reasonable strategy where anatomically feasible; however, the evidence for its superiority is mixed.

Timing. Perform it as soon as possible. In the septic foot, control infection and drainage first (urgent debridement/drainage may precede revascularisation), then revascularise to support healing of the debrided wound; the sequence is individualised.

Patient selection and shared decision-making. In frail, medically complex or non-ambulatory patients, weigh limb salvage against procedural risk, likely function and goals of care — primary amputation may sometimes offer better function and quality of life. Use WIfI to estimate benefit [11].

Surgical Treatment

Surgery spans a wide spectrum, from emergency source control to elective reconstruction [1,5,11]:

• Incision and drainage (I&D) — urgent for abscess, deep infection or compartment syndrome.
• Removal of infected/necrotic tissue — debridement (Section 12).
• Partial bone resection — for DFO or a source of pressure.
• Minor amputation (toe/ray/transmetatarsal) — limb-preserving source control that removes infected bone while preserving a functional stump.
• Major amputation (below/above knee) — for an unsalvageable limb, uncontrolled infection, intractable ischaemic pain, or when it offers better function/survival.
• Reconstruction / flap coverage / skin grafting — to close large defects once infection is controlled and perfusion is adequate.
• Deformity correction / surgical offloading (Section 15).
• Charcot stabilisation (Section 25).

Indications, timing, risk, outcome and postoperative care are individualised. Source control is urgent in sepsis, necrotising infection or wet gangrene; reconstruction is staged after infection control and optimisation of perfusion. Postoperative care includes offloading, wound management, perfusion support, infection surveillance and rehabilitation.

Negative Pressure Wound Therapy (NPWT)

Mechanism. Sub-atmospheric pressure promotes granulation through macrostrain (wound contraction) and microstrain (cellular proliferation), reduces oedema and exudate, and approximates the wound edges.

Guideline position (IWGDF 2023). In addition to best standard care, NPWT may be considered to reduce wound size in postoperative (surgical) foot wounds ([Moderate] evidence) [7,8]. The evidence for non-surgical/primary chronic DFUs is weaker ([Low/Moderate]); it does not substitute for first-line debridement, offloading, perfusion and infection control.

NPWT with instillation (NPWTi). This delivers topical solutions during therapy for heavily contaminated/biofilm-laden wounds; it is assessed separately and remains an evolving, lower-certainty area of evidence.

Advanced and Adjunctive Therapies

Framework. These therapies are considered only after best standard care has been optimised and when a wound is not progressing (typically still not healing after approximately 4–6 weeks of optimised care) and resources permit. IWGDF 2023 made conditional, supportive recommendations for a short list; most of the remaining modalities remain investigational or unsupported for routine use [7,8].

Biofilm and Antimicrobial Resistance

Biofilm — structured microbial communities embedded in an extracellular polymeric matrix — is an important contributor to wound chronicity; it tolerates host defences and antimicrobials. It is largely invisible clinically, and routine diagnostic methods cannot reliably detect or quantify it at the bedside.

At the core of management is repeated (frequent) sharp debridement — mechanical disruption is the most reliable antibiofilm step. This is accompanied by topical antimicrobials/antiseptics (dilute hypochlorous acid, PHMB, iodine, silver) and surfactant-based cleansers; emerging antibiofilm agents remain lower-certainty adjuncts.

Antimicrobial resistance (AMR) is a separate concern: DFIs increasingly involve resistant organisms (MRSA, resistant gram-negatives). Stewardship is essential here — culture-directed therapy, avoiding antibiotics in uninfected wounds, restricting broad-spectrum agents to severe infections, the narrowest effective spectrum, the shortest effective duration, and prompt de-escalation according to culture data [5].

Charcot Neuroarthropathy (CNO)

Acute Charcot is a limb-threatening neuro-inflammatory process that leads to destruction of bone and joints in a neuropathic, well-perfused foot.

Differential diagnosis. Distinguishing acute CNO from infection/cellulitis (DFI), gout, DVT and osteomyelitis is critical but often difficult. Suspect CNO in any neuropathic patient who presents with a warm, swollen, erythematous foot, frequently without an open wound or systemic infection; erythema that diminishes on elevation favours CNO over infection. If an ulcer overlying the deformity is also present, distinguishing CNO from osteomyelitis may require MRI (and sometimes advanced/nuclear imaging or bone biopsy) [1].

Imaging. Radiographs (fragmentation/dislocation); MRI to assess early bone marrow oedema and coexisting osteomyelitis.

Treatment. Early immobilisation and offloading until the acute inflammatory phase resolves (monitored by the reduction in skin temperature difference and by clinical/radiographic stabilisation) — typically a non-removable total contact cast. Avoid weight-bearing until then. Prolonged offloading is often necessary.

Surgery. Reserved for unstable/severe deformity, recurrent ulceration over bony prominences, or instability that cannot be managed conservatively.

Ulcer prevention in the deformed Charcot foot. Custom footwear/orthoses to accommodate rigid deformities (e.g. rocker-bottom foot), exostectomy when indicated, and close surveillance.

The Multidisciplinary Care Model

Strong evidence and consistent guideline endorsement support multidisciplinary foot-care teams for reducing amputations and improving outcomes; the introduction of such a team has been associated with reductions in major amputation of up to 50–70% [1,3].

Ideal team roles

• Endocrinology/diabetology — glycaemic and metabolic optimisation
• Vascular surgery — perfusion assessment and revascularisation
• Infectious diseases — antibiotic strategy and stewardship
• Orthopaedic/podiatric surgery — debridement, offloading surgery, deformity and Charcot correction, amputations
• Podiatry — debridement, offloading, nail and callus care, prevention
• Wound-care nursing — dressings, monitoring, education
• Radiology — imaging and interventional support
• Rehabilitation/PT/OT — mobility, gait, post-amputation rehabilitation
• Nutrition — correction of deficiencies, dietary support
• Orthotics and prosthetics — footwear, insoles, prostheses
• Primary care — coordination, risk factor management, follow-up

Referral pathways. Rapid access for new ulcers, suspected infection or ischaemia, non-healing wounds and Charcot; same-day or emergency pathways for limb-threatening presentations (Section 28).

Monitoring Healing

Objective follow-up. At every visit, assess wound area (planimetry/photography), depth and volume, granulation quality, exudate, signs of infection, perfusion status, pain and the periwound skin [27].

The key prognostic marker: percentage area reduction (PAR) at approximately 4 weeks. Failure to achieve roughly a 50% area reduction at 4 weeks predicts poor healing at 12 weeks and should trigger reassessment [1,27].

Stalled wound / treatment failure. This describes a wound that fails to progress over approximately 4 weeks despite apparently appropriate care.

When a wound stalls, reassess the "big five": (1) the diagnosis (is this really a straightforward DFU? consider malignancy, an atypical cause, Charcot); (2) perfusion (reassess for ischaemia/revascularisation — repeat non-invasive arterial testing); (3) infection/osteomyelitis (exclude occult DFO with radiography/MRI); (4) offloading adherence and adequacy (is the device actually being worn? switch to a non-removable or adherence-enforcing device); (5) nutrition, glycaemia and comorbidities. Only then should the appropriateness of adjunctive therapy be considered.

Technology. Digital photography, planimetry, thermal imaging (temperature asymmetry as an early signal of inflammation or a pre-ulcerative lesion) and remote/telemedicine monitoring can all support surveillance.

Urgent Warning Signs (Red Flags)

• Sepsis / systemic toxicity (hypotension, altered consciousness, tachypnoea) — Emergency: resuscitation, IV antibiotics, urgent surgical assessment
• Rapidly spreading cellulitis (advancing erythema extending beyond the ankle) — Same-day hospital assessment
• Necrotising soft tissue infection (severe or disproportionate pain, bullae, skin necrosis, crepitus, "dishwater" exudate) — Emergency surgery
• Wet gangrene — Emergency surgical source control
• Deep abscess / fluctuance — Urgent I&D
• Crepitus / gas in the tissues — Emergency: gas-forming infection
• Acute limb ischaemia (sudden cold, pale, painful, pulseless foot) — Vascular emergency
• Chronic limb-threatening ischaemia (CLTI) — Urgent vascular referral
• Rapid tissue necrosis — Same-day surgical assessment
• Exposed or infected bone — Urgent assessment for DFO/surgery
• Uncontrolled bleeding — Emergency
• Severe metabolic decompensation (e.g. DKA/HHS with foot sepsis) — Emergency

Preventing Recurrence

A healed ulcer is not a cure but a state of remission (recurrence of approximately 40% at 1 year, 60% at 3 years and 65% at 5 years) [2,3]. Prevention is therefore lifelong [1].

Recurrence-prevention checklist

• Daily foot inspection (by the patient or caregiver; a mirror or an assistant if vision or mobility is limited)
• Skin care (emollients; avoiding interdigital maceration) and safe professional nail care
• Professional callus management (never self-cutting or "bathroom surgery")
• Footwear assessment; therapeutic footwear with pressure-relieving features (rocker soles, metatarsal accommodations) plus custom insoles
• Home foot-temperature or pressure monitoring in high-risk patients (asymmetry as an early warning)
• Smoking cessation
• Glycaemic and cardiovascular/blood pressure risk management
• Regular podiatric/foot-team review at risk-based intervals
• Structured patient education; early reporting of any change in the skin
• Risk-stratified follow-up frequency (higher risk → more frequent review)

Patient and Caregiver Education

Do

• Inspect both feet every day (tops, soles, between the toes, heels); use a mirror or ask for help if needed.
• Wash daily with lukewarm (not hot) water, dry thoroughly (especially between the toes) and moisturise dry skin on the heels and soles (but not between the toes).
• Check the water temperature with your hand or elbow, or with a thermometer, before bathing (neuropathy can mask hot water).
• Always wear well-fitting shoes and clean socks; check inside your shoes for stones or objects before putting them on.
• Attend scheduled foot-care and diabetes appointments; keep your blood glucose well managed.

Do not

• Never walk barefoot, indoors or outdoors.
• Never cut your own calluses or corns, and never remove necrotic tissue yourself.
• Do not apply heating pads or hot water bottles to your feet.
• Do not use "bathroom surgery", caustic corn removers, strong antiseptics or unproven home remedies on wounds.
• Do not ignore a new wound, blister, colour change, swelling, increased warmth, discharge or odour.

Special Populations

CKD / dialysis. These patients face a very high risk of ulceration and amputation, extremely high rates of medial arterial calcification and critical ischaemia, blunted inflammatory markers, complex fluid and nutritional status, and drug-dosing constraints; tissue healing is markedly impaired. Aggressive surveillance and careful antibiotic dosing are required.

Older or frail adults. Weigh treatment burden, function and goals of care; prioritise quality of life, pain control and mobility. Falls risk influences offloading choices; extensive limb-salvage surgery may not align with goals of care, and primary amputation sometimes preserves function better.

Severe PAD. Perfusion assessment and revascularisation take priority; dry ischaemic eschar is debrided conservatively until perfusion has been addressed.

Immunosuppression. The inflammatory response is atypical or blunted; maintain a lower threshold for MRI, investigation of deep infection and hospital admission.

Obesity/malnutrition. Address nutrition and mobility; bear in mind the inconsistent relationship between obesity and outcomes [28].

Cognitive impairment. Rely on caregivers for inspection and adherence; simplify regimens; consider non-removable offloading to enforce adherence.

Limited mobility. Adapt offloading and pressure management; provide heel protection.

Previous amputation. The highest risk of recurrence; intensive prevention and prosthetic/orthotic optimisation are required.

Low-resource settings. Prioritise the accessible cornerstones (offloading, debridement, infection control, education); high-cost adjunctive therapies are often unavailable — prioritise equitable, cost-effective care [1].

Clinical Decision Algorithms

32.1 Newly identified DFU

1. Stabilise: first check for systemic sepsis or emergency red flags.
2. Assess the person, the limb, the foot and the wound (Section 6); cleanse, probe to bone, measure the dimensions.
3. Screen perfusion (pulses plus ABI/TBI/toe pressure), infection (clinically), neuropathy (10-g monofilament) and depth/PTB.
4. Classify (SINBAD/UT + WIfI + IWGDF/IDSA infection).
5. Address the cornerstones: debride, offload, moisture balance, glycaemia and nutrition, education.
6. Establish a baseline measurement/photograph; arrange multidisciplinary follow-up within 1–2 weeks.
7. Escalate if infection, ischaemia or deep structures are involved (branch to 32.2–32.4/32.6).

32.2 Suspected infection

1. Diagnose infection clinically (≥2 signs of inflammation).
2. Grade the severity (IWGDF/IDSA: mild/moderate/severe ± O).
3. Deep tissue culture after debridement; check CRP/ESR/PCT if uncertain; imaging if deep or bone involvement is suspected.
4. Empirical antibiotics according to severity and risk; admit severe or complicated moderate cases.
5. Emergency surgery for abscess, necrotising infection, wet gangrene or gas.
6. De-escalate according to culture; set duration according to soft tissue versus bone involvement.

32.3 Suspected ischaemia

1. Palpate the pulses; measure ABI/TBI/toe pressure/TcpO₂ (interpret ABI with caution — calcification).
2. If perfusion is impaired or the wound is not healing → urgent vascular referral.
3. Anatomical imaging (duplex → CTA/MRA/angiography).
4. In the septic foot, control the infection and drainage first; then revascularise (endovascular versus open).
5. Limit aggressive debridement of dry ischaemic eschar until perfusion has been addressed.

32.4 Suspected osteomyelitis

1. PTB + radiography + CRP/ESR.
2. If inconclusive or suspicion is positive → MRI.
3. Bone biopsy and culture to confirm and guide treatment (particularly if empirical therapy fails or a prolonged course is being considered).
4. Decide between medical management (approximately 6 weeks, culture-directed) and surgical resection (shorter antibiotic course).
5. Monitor markers and imaging; maintain surveillance for recurrence (remission ≠ cure).

32.5 Wound not healing after 4 weeks

1. Confirm approximately 50% area reduction at 4 weeks; if not achieved, reassess.
2. Recheck the diagnosis, perfusion, infection/DFO, offloading adherence, and nutrition/glycaemia.
3. Correct the missing cornerstone.
4. Only then consider adjunctive therapy (Section 23) if appropriate.

32.6 Emergency / limb-threatening pathway

1. Recognise the red flags (Section 28).
2. Resuscitate (ABCs, IV fluids, glucose), broad-spectrum IV antibiotics.
3. Involve surgery and vascular services immediately.
4. Urgent source control (I&D, debridement, amputation where required) ± emergency revascularisation.

Treatment Comparison Matrix

Evidence quality reflects GRADE-style certainty from IWGDF 2023 and related reviews; "healing/amputation benefit" is directional and context-dependent.

Evidence Summary

Strong / well supported (standard of care)

• Multidisciplinary team care to reduce amputation (reduction of up to 50–70% in major amputation) [1,3]
• Perfusion assessment ± revascularisation for ischaemic or limb-threatening wounds [11]
• Clinical diagnosis of infection and culture-directed treatment; no antibiotics for uninfected ulcers [5]
• Sharp/surgical debridement as first-line management for most wounds [1,7]
• Non-removable knee-high offloading (TCC/iTCC) for plantar neuropathic ulcers [1,12]
• Dressing selection based on exudate, comfort and cost rather than "more advanced = better" [7]

Moderate / conditional (selected patients, adjunctive to optimised standard care)

• Sucrose octasulfate dressing (uninfected neuroischaemic, stalled) [7]
• Autologous leucocyte/platelet/fibrin patch; placenta-derived products [7]
• NPWT for postoperative foot wounds [7]
• HBOT for non-healing neuroischaemic ulcers [7,8]
• Bioengineered skin/cellular-tissue products for clean, non-healing ulcers after standard care has failed (heterogeneous)

Insufficient / conflicting

• Topical oxygen (supportive but low or contested certainty) [7,33]
• PRP, growth factors, many skin/cellular substitutes (heterogeneity, sponsorship) [7]
• Electrical stimulation, ultrasound, shockwave, photobiomodulation
• NPWT for primary (non-surgical) chronic DFUs
• Most nutritional supplements in the absence of a documented deficiency

Should NOT be used routinely

• Antibiotics for clinically uninfected ulcers [5]
• Collagen/alginate dressings for the purpose of healing; topical phenytoin; herbal-impregnated dressings for healing alone [7]
• Hydrogen peroxide as a routine wound cleanser

Where guidelines and experts disagree: topical oxygen therapy (differing recommendations across guideline versions and organisations), the superiority of angiosome-directed revascularisation, optimal antibiotic durations (particularly the trend towards shorter courses in DFO after resection), the role and selection of cellular/tissue products, and the optimal timing of revascularisation relative to minor amputation in complex neuroischaemic feet.

Emerging Research and Future Directions

AI in wound imaging and prognosis. Machine learning models applied to smartphone or standardised wound photography for automated measurement, tissue classification and prediction of the healing trajectory; promising for standardisation and remote triage.

Smart dressings and wearables. In-shoe sensors that detect temperature rises (early inflammation or Charcot) and pressure alert patients via an app; dressings with pH and moisture sensors are also in development. Given the strong link between pressure and inflammation and (re-)ulceration, these are among the most clinically promising technologies in the near term.

Personalised antimicrobial therapy. Rapid molecular diagnostics and stewardship-guided regimens; bacteriophage therapy targeting specific multidrug-resistant biofilms (under investigation).

Regenerative medicine / tissue engineering. Improved skin substitutes, exosome/EV therapeutics and bioprinting — mechanistically attractive, but still early.

Predictive biomarkers. Inflammatory and proteomic markers to identify wounds that will stall and to target adjuncts earlier.

Remote multidisciplinary care / telemedicine. Expanding access, particularly for underserved and rural populations.

The most clinically promising developments in the near term are: sensor-based monitoring for prevention (temperature/pressure), AI-assisted wound assessment for standardisation and triage, and better patient-selection tools for existing adjuncts. What these have in common is that they leverage, rather than replace, the established high-impact levers (offloading, early detection, perfusion and infection control).

Research Gaps

Unresolved questions. Which adjuncts genuinely improve patient-centred outcomes (amputation-free survival, function, quality of life) rather than the surrogate of area reduction; optimal antibiotic durations; the best offloading strategy in the presence of infection or ischaemia; the optimal timing of revascularisation relative to minor amputation; and how biofilm can be reliably identified and treated.

Weaknesses in the trial literature. A lack of high-quality, non-industry-sponsored RCTs; small sample sizes; inconsistent outcome definitions (complete healing versus area reduction versus time to healing; "healed" versus "remission"); frequent conflicts of interest; inadequate blinding (difficult for device trials); short follow-up (missing recurrence, amputation and mortality); and exclusion of ischaemic, infected and complex patients, which limits real-world applicability.

Priorities. Large, independent, adequately powered RCTs with standardised, patient-centred endpoints and long follow-up; pragmatic trials in real-world complex patients; cost-effectiveness and equity analyses; and better diagnostic tools for perfusion, infection and biofilm.

Final Conclusions

Practical standard care in DFUs is a disciplined package delivered by a multidisciplinary team: early detection, rigorous perfusion assessment (with revascularisation where perfusion is inadequate), prompt diagnosis and control of infection (managing osteomyelitis on its own terms and not treating uninfected wounds with antibiotics), first-line debridement and effective offloading (ideally a non-removable knee-high device for plantar neuropathic ulcers). All of this is underpinned by moisture balance, glycaemic and nutritional optimisation, comorbidity management and patient education.

Advanced and adjunctive therapies — sucrose octasulfate dressing, autologous leucocyte/platelet/fibrin patch, placental products, NPWT for postoperative wounds, HBOT for neuroischaemic ulcers and selected cellular/tissue products — should be considered only after standard care has been optimised and a wound has failed to progress, strictly as an adjunct and where resources permit. Most other advanced modalities remain investigational.

Clinical Scenarios

Scenario 1 — Superficial neuropathic plantar ulcer, no infection or ischaemia

• Assessment: confirm neuropathy (monofilament), confirm adequate perfusion (pulses/ABI–TBI — rule out ischaemia), no signs of infection, measure/photograph, map pressure points and callus.
• Offloading: first-line non-removable knee-high device (TCC/iTCC); if not tolerated, a removable walker (with adherence education).
• Debridement: sharp debridement of surrounding callus and non-viable tissue at every visit.
• Dressing: simple, matched to exudate, comfortable, low cost (e.g. foam or hydrogel depending on exudate).
• Follow-up: weekly review; expect and track roughly a 50% reduction in area by 4 weeks.
• Milestones: progressive area reduction → healing within weeks provided adherence is maintained; if progress stalls at 4 weeks, apply the reassessment checklist.

Scenario 2 — Moderately infected ulcer with surrounding cellulitis

• Infection classification: probably moderate (>2 cm erythema or involvement of deeper structures) — check for systemic features (these would make it severe).
• Culture strategy: deep tissue curettage after debridement (not a superficial swab); CRP/ESR/PCT if uncertain.
• Imaging: plain radiography (exclude gas/DFO) ± MRI if a deep abscess or DFO is suspected.
• Antibiotic principles: empirical cover according to severity and risk (GPC ± GNR/anaerobes; MRSA/Pseudomonas according to risk); de-escalate on culture results.
• Surgical indications: abscess/necrosis/gas → urgent I&D/debridement.
• Hospital admission: for severe disease, or for moderate disease with complicating factors (ischaemia, need for IV therapy, poor home care, frailty, hyperglycaemia/metabolic decompensation).

Scenario 3 — Ischaemic ulcer with absent pulses

• Vascular testing: urgent ABI/TBI/toe pressure/TcpO₂ (interpret ABI with caution — calcification), then duplex → CTA/MRA/angiography.
• Urgency: urgent vascular referral for angiography / immediate consultation; emergency if acute limb ischaemia is present.
• Revascularisation assessment: endovascular versus open according to anatomy and risk; integrate WIfI; shared decision-making in frail patients.
• Debridement precautions: avoid aggressive sharp debridement of dry, stable, uninfected ischaemic eschar until perfusion has been addressed (risk of accelerating gangrene); control infection first.
• Wound-care modifications: keep dry eschar dry and protected; prioritise perfusion; conservative local care until revascularisation is achieved.

Scenario 4 — Ulcer with suspected osteomyelitis

• PTB: perform it; a positive result in an infected wound raises the probability.
• Laboratory: CRP/ESR (may be normal — this does not exclude the diagnosis).
• Imaging sequence: radiography → MRI if inconclusive or equivocal.
• Bone biopsy: percutaneous or open — the reference standard for diagnosis and for culture-directed therapy.
• Medical versus surgical: selected forefoot DFO with adequate perfusion → approximately 6 weeks of culture-directed antibiotics; extensive/necrotic disease, abscess, deformity or failure of medical therapy → surgical resection (with a shorter antibiotic course).

Scenario 5 — Ulcer failing to heal after 4–6 weeks of apparently appropriate care

• Reassessment checklist: re-confirm the diagnosis (atypical cause/malignancy/Charcot?).
• Offloading adherence: verify device use (if adherence is the problem, switch to a non-removable or adherence-enforcing device).
• Perfusion: reassess for ischaemia and revascularisation (repeat non-invasive arterial testing).
• Infection: re-examine for occult infection/DFO (radiography/MRI).
• Nutrition/glycaemia/comorbidities: correct deficiencies, optimise control (check HbA1c and nutritional status).
• Eligibility for advanced therapies: only once the fundamentals have been optimised and the wound is clean — consider sucrose octasulfate (neuroischaemic), leucocyte/platelet/fibrin patch, placental products, tissue-engineered skin substitutes, NPWT (postoperative) or topical oxygen/HBOT (neuroischaemic), according to wound type and available resources.

Glossary

Abbreviations

Plain-Language Patient Summary

Diabetes can damage the nerves and blood vessels in your feet, which means a small injury may go unnoticed and then heal slowly. Foot ulcers are common and they are serious — but most of them can heal with good care, and future ones can very often be prevented.

The things that help healing the most:

1. Take the pressure off the wound. For wounds on the sole of the foot, a special cast or boot (sometimes one you cannot take off yourself) works best. Use it exactly as you are told.
2. Let your team clean the wound properly. A clinician will remove dead skin and hard callus — never do this yourself.
3. Treat infection quickly. Redness, warmth, swelling, pus, a bad smell, or simply feeling unwell all mean you need to be seen straight away.
4. Get your blood flow checked. If the foot is cold, pale or very painful, or if the wound is not healing, you may need a blood-flow test and possibly a procedure to improve the circulation.
5. Manage your blood sugar and your diet, and stop smoking. All of these help wounds heal.

Every day: look at every part of both feet (use a mirror or ask someone to help), wash and dry them gently (especially between the toes), moisturise dry skin on the heels and soles, check inside your shoes for stones before putting them on, wear well-fitting shoes, and never walk barefoot — not even indoors.

Once a wound has healed, it is not quite the same as being "cured" — the risk of a new one stays high. That is why you should keep up the daily checks, wear the shoes and insoles you have been prescribed, and go to your regular foot check-ups.

References

The identifiers below refer to the actual sources consulted for this synthesis. The guideline chapters should be read in full for complete effect estimates and their own citation chains.

1. Schaper NC, van Netten JJ, Apelqvist J, Bus SA, Fitridge R, Game F, Monteiro-Soares M, Senneville E; IWGDF Editorial Board. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3657. DOI: 10.1002/dmrr.3657. URL: https://onlinelibrary.wiley.com/doi/10.1002/dmrr.3657 · IWGDF PDF: https://iwgdfguidelines.org/wp-content/uploads/2023/07/IWGDF-2023-01-Practical-Guidelines.pdf
2. McDermott K, Fang M, Boulton AJM, Selvin E, Hicks CW. Etiology, Epidemiology, and Disparities in the Burden of Diabetic Foot Ulcers. Diabetes Care. 2023;46(1):209–221. URL: https://diabetesjournals.org/care/article/46/1/209/148198 · PubMed: https://pubmed.ncbi.nlm.nih.gov/36548709/
3. Armstrong DG, Tan T-W, Boulton AJM, Bus SA. Diabetic Foot Ulcers: A Review. JAMA. 2023. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC10723802/ (summary via Keck Medicine of USC: https://medresources.keckmedicine.org/news/novel-jama-study-on-diabetic-foot-ulcers-best-practices-for-treatment-and-prevention)
4. Nature Scientific Reports long-term mortality cohort (2019) and related peer-reviewed burden/mortality reviews; WHO/IWGDF 2023–2024 consensus data on amputation and mortality burden.
5. Senneville É, Albalawi Z, van Asten SA, Abbas ZG, Allison G, Aragón-Sánchez J, et al. IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023). Clinical Infectious Diseases. 2023. DOI: 10.1093/cid/ciad527. URL: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad527/7287196 · IWGDF PDF: https://iwgdfguidelines.org/wp-content/uploads/2023/07/IWGDF-2023-04-Infection-Guideline.pdf · IDSA: https://www.idsociety.org/practice-guideline/diabetic-foot-infections/
6. Monteiro-Soares M, Hamilton EJ, Russell DA, Sirisawasdi G, Boyko EJ, Mills JL, et al. Guidelines on the classification of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2023;e3648. IWGDF PDF: https://iwgdfguidelines.org/wp-content/uploads/2023/07/IWGDF-2023-03-Classification-Guideline.pdf
7. Chen P, Vilorio NC, Dhatariya K, Jeffcoate W, Lobmann R, McIntosh C, et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3644. DOI: 10.1002/dmrr.3644. URL: https://onlinelibrary.wiley.com/doi/10.1002/dmrr.3644 · IWGDF PDF: https://iwgdfguidelines.org/wp-content/uploads/2023/07/IWGDF-2023-07-Wound-Healing-Guideline.pdf
8. IWGDF. Guidelines (2023 update) — full guideline suite (prevention, classification, infection [with IDSA], PAD [with ESVS/SVS], offloading, wound healing, Charcot). URL: https://iwgdfguidelines.org/guidelines-2023/
9. StatPearls (NCBI Bookshelf). Diabetic Foot Ulceration and Complications. Updated 2026. URL: https://www.ncbi.nlm.nih.gov/books/NBK499887/ (nutrition/protein targets and recurrence figures)
10. American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S261–S276. DOI: 10.2337/dc26-S012. URL: https://diabetesjournals.org/care/article/49/Supplement_1/S261 · PubMed: https://pubmed.ncbi.nlm.nih.gov/41358886/ · PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12690177/
11. Fitridge R, Chuter VH, Mills JL, Hinchliffe RJ, Azuma N, Behrendt C-A, et al. The intersocietal IWGDF, ESVS, SVS guidelines on peripheral artery disease in people with diabetes and a foot ulcer (2023). Diabetes/Metabolism Research and Reviews / EJVES. Referenced within IWGDF 2023 suite: https://iwgdfguidelines.org/guidelines-2023/
12. Bus SA, Armstrong DG, Crews RT, Gooday C, Jarl G, Kirketerp-Møller K, et al. Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024. IWGDF PDF: https://iwgdfguidelines.org/wp-content/uploads/2023/07/IWGDF-2023-06-Offloading-Guideline.pdf
13. American Diabetes Association. Summary of Revisions: Standards of Care in Diabetes—2026. Diabetes Care. 2026. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12690167/

Additional context sources consulted: a global systematic review of DFU prevalence (approximately 6.3%); the endocrinologyadvisor.com summary of the 2023 IWGDF/IDSA infection guideline; the Medscape/eMedicine "Diabetic Foot Ulcers Guidelines" summary (2025 update); The Mayer Institute (2026) topical-oxygen evidence summary (citing Chen et al., IWGDF 2023 wound-healing guideline) [33]. Full identifiers are available on the pages linked above.